14th Annual Meeting of the Safety Pharmacology Society: threading through scientific sessions for originality and novelty. (June 2015)

• Record Type: Journal Article
• Authors: Cavero, Icilio
• Is Part Of: Expert opinion on drug safety. Volume 14:Number 6(2015:Nov.)
• Page Start: 999
• Page End: 1008
• Publication Date: 2015-06
• Subjects: Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1517/14740338.2015.1034104
• Languages: English
• ISSNs: 1474-0338

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <italic> <bold>Introduction:</bold> </italic> The Annual Meeting of the Safety Pharmacology (SP) Society is a yearly event designed to keep attendees abreast of how to best identify and mitigate organ function liabilities of candidate drugs selected for clinical assessment.</p> <p> <bold> <italic>Areas covered:</italic> </bold> Heart rate (HR) and blood pressure (BP) effects of candidate drugs in dogs/monkeys have satisfactory human translation. Mechanism-designed assays offer opportunities for innovative approaches to identify chemotherapeutic-induced peripheral neuropathy (PN). SP has a large array of methodologies to determine safety on eye functions. Video-tracking analysis of zebrafish swimming behavior accurately profiles drugs for high-level brain function liabilities. Available <italic>in vitro</italic> and <italic>in vivo</italic> assays can identify, and determine physiological and pharmacological mechanisms of, candidate drug-induced emesis. <italic>Ad hoc</italic> Working Groups have already finalized protocols for testing the comprehensive <italic>in vitro</italic> arrhythmia assay (C<italic>i</italic>PA), an innovative paradigm for assessing mechanisms conferring candidate drug proarrhythmic liabilities.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> The good concordance of non-clinical and clinical Phase I BP and HR effects of candidate drugs support the use of dog/monkey models for clinical outcome. Drug liabilities (e.g., PN, nausea, vomiting, etc.) affecting non-vital organs/systems require the same degree of SP attention given to vital functions as they can dramatically reduce patient quality of life.</p> </abstract>